Method Of Use Patents Gaining Greater Importance In The Eyes Of Pharma
Large pharmaceutical manufacturers are beginning to see method of use patents as a more valuable piece of their patent portfolios, Gene Logic CEO Mark Gessler said at the Biotechnology Industry Organization/Windhover Partnering Conference for Decision Makers in Washington, D.C. May 17
You may also be interested in...
FDA is developing a process to inform innovators and generic companies when part of a brand drug's labeling can be "carved out" of an ANDA, Associate Counsel for Drugs Elizabeth Dickinson said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials